Healthcare systemBurden of diseasePatient journeyNontuberculous mycobacterial lung disease (NTM-LD) is a rare but growing health concern, particularly affecting vulnerable patients with chronic lung conditions. Understanding the patients' perspective on their disease and treatment expectations can help to ...
Insmed plans to launch ARIKAYCE first in Germany, followed by the United Kingdom (UK) and other EU markets, subject to local reimbursement processes. As part of Insmed's comprehensive approach to patient support, the Company has established country-s...
When diagnosing NTM-LD, each patient had a chest X-ray and if the changes were difficult to define or very advanced, then the patient had a chest CT. Over the years there are more often cases of mycobacteriosis with caves and involvement of both lungs. In comparison, there were about ...
[9] First Type 1 Diabetes Patient in Europe is Free from Insulin Therapy after Undergoing Diabetes Research Institute's BioHub Transplant Technique.Retrieved Jun 9, 2016 fromhttps://www.prnewswire.com/news-releases/first-type-1-diabetes-patient-in-eur...
[58] Chambergo-Michilot D,Alur A,Kulkarni S,et al. Mipomersen in familial hypercholesterolemia:an update on health-related quality of life and patient-reported outcomes[J]. Vasc Health Risk Manag,2022,18:73-80. [59]Astaneh B,Makhdami N,Astaneh V,...
Ellinghaus for her excellent guidance, for being extremely patient with my writing, for being supportive, understanding and providing me with an excellent research atmosphere. I would like to thank late Dr. Biswamoy Pati who has always been supportive and inspiring. I would always be grateful to...
【摘要】雷帕霉素是哺乳动物雷帕霉素靶蛋白(mTOR)受体抑制剂。临床对mTOR信号通路及其对肿瘤发生和血管增殖下游作用的认识进展,拓宽了mTOR抑制剂在许多具有挑战性疾病中的临床应用。口服雷帕霉素用于治疗肾移植、肺淋巴管平滑肌瘤病、结节性硬化症(TSC)等,但系统治...